Key Highlights
- Total Revenue was USD 106.1 million in the third quarter of 2026, down 1.6% from USD 107.8 million, as U.S. net product sales growth was offset by timing of inventory sales to ex-U.S. partners.
- Income from operations rose 21.9% to USD 42.2 million from USD 34.6 million, driven by higher U.S. net product sales, partly offset by higher commercial expenses.
- Innoviva (NASDAQ:INVA) reported a net loss of USD 73.9 million, or USD 1.03 per share, against Net Income of USD 89.9 million, after a USD 139.5 million net unfavorable swing in Investment values.
- U.S. net product sales rose 45% to USD 43.3 million, led by GIAPREZA at USD 23.1 million and XACDURO at USD 16.1 million, while gross GSK royalties held steady at USD 58.1 million.
Product Sales Growth Lifts Operating Income
Innoviva (NASDAQ:INVA) filed its Quarterly Report on November 4, 2026 for the period ended September 30. The company is a diversified biopharmaceutical firm with a Royalty portfolio tied to GSK respiratory products, a hospital-focused critical care and infectious disease unit called Innoviva Specialty Therapeutics, and strategic healthcare investments. Net product sales were USD 49.4 million, made up of USD 43.3 million in the U.S. and USD 6.1 million ex-U.S. U.S. sales increased from USD 29.9 million, with XERAVA adding USD 3.4 million. Operating Income reached USD 42.2 million, though interest expense rose to USD 5.5 million from USD 4.0 million. NUZOLVENCE, approved on December 12, 2025, is now commercially available in the U.S.
How Fair-Value Markdowns Turned Profit Into a Loss
The company accounts for several strategic holdings at fair value, so price moves flow straight into earnings. Net unfavorable changes of USD 139.5 million were primarily attributable to a decline in the stock price of Armata at quarter-end, according to the filing. Pre-tax results swung to a loss of USD 97.6 million from income of USD 97.8 million, and a USD 23.7 million tax benefit narrowed the net loss to USD 73.9 million. Prior-year diluted EPS was USD 1.08 against USD 1.30 basic. Strategic investments were valued at USD 535.5 million: USD 323.7 million in Armata, USD 179.9 million in other Equity and convertible debt, and USD 31.9 million in the ISP Fund. Nine-month net income was USD 29.3 million, or USD 0.40 per share, versus USD 107.0 million.
Royalty Stability, Cash and the Buyback
Royalties from GSK stayed flat at USD 58.1 million gross. Innoviva earns 15% on the first USD 3.0 billion of annual global net sales of RELVAR and BREO ELLIPTA and 5% above that, with ANORO ELLIPTA royalties tiering upward. Cash was USD 581.4 million, receivables were USD 102.1 million, and long-term Debt net of discount and issuance costs was USD 258.8 million. In the quarter it repurchased 1,226,948 shares for USD 26.3 million under a USD 125 million program, bringing the total to 3,829,116 shares for USD 82.7 million. Risks flagged include lower royalty revenue, commercialization of its products and the unpredictable value of its investments. The filing gives no guidance.
Where Things Stand
Yes, in large part. Innoviva (NASDAQ:INVA) lifted operating income 21.9% to USD 42.2 million while a USD 139.5 million fair-value decline, mainly tied to Armata, produced the USD 73.9 million net loss. Offsetting that, revenue slipped 1.6% and interest expense rose. Because the holdings are marked to market, quarterly profit can swing sharply with share prices. Next markers are U.S. sales of NUZOLVENCE and XACDURO, steadiness of GSK royalties, the carrying value of Armata, and continued buybacks.






Please wait processing your request...